Research on the drugs used to treat cancer and how well they work. Covers immunotherapy, chemotherapy-free regimens, biosimilars, targeted drugs, and treatment costs.
Researchers at Mount Sinai present promising findings on innovative treatments for recurrent ovarian cancer, molecular profiling of bile duct and gallbladder cancers, and adjuvant therapy for melanoma. The studies demonstrate encouraging results for patients with these rare and often fatal diseases.
Researchers have found that crizotinib produces significant responses in patients with intermediate and high MET amplification, resulting in a 60-67% overall objective response rate. The drug showed early activity against MET-dependent cells in preclinical laboratory studies.
OMP-54F28, a Wnt inhibitor targeting cancer stem cells, has shown promising results in a Phase I clinical trial. The drug was generally well-tolerated and resulted in stable disease for over six months in several patients with advanced solid tumors.
A University of Colorado Cancer Center study found NTRK1 mutations in over 1% of non-small cell lung cancer patients. The study also developed a test for rapid detection of NTRK1 oncogenes, marking a new frontier in lung cancer treatment.
Researchers presented promising results from four clinical trials featuring new targeted drugs for advanced ovarian, lung and thyroid cancers, as well as chronic lymphocytic leukemia. These treatments showed potential to slow disease progression and improve survival rates for patients with relapses or treatment resistance.
Researchers report promising results from a phase I study on MPDL3280A, an investigational drug for treating advanced bladder cancer. The trial showed improved response rates among patients with PD-L1-positive tumors, with 7% achieving complete responses.
A phase 3 study found that ibrutinib significantly lengthened progression-free survival as a second-line therapy for CLL, with 86% of patients on ibrutinib experiencing durable responses. Ibrutinib also showed superior results compared to ofatumumab in terms of overall survival and partial response rates.
The American Society for Clinical Oncology has released new clinical guidelines for cancer-related fatigue, developed in collaboration with Moffitt Cancer Center. The guidelines recommend regular screening and treatment of fatigue in cancer patients after treatment, as well as addressing other contributing factors such as depression, p...
Jackson Laboratory Assistant Professors Jennifer Trowbridge and Chengkai Dai have received federal research grants to investigate acute myeloid leukemia and metformin's anti-cancer effects. They aim to elucidate specific problems in key areas of cancer research.
Researchers found that discontinuing statins in patients with advanced illnesses resulted in improved overall quality of life and lower costs without increased deaths. Patients who stopped taking statins appeared to live slightly longer, with median survival times of 229 days compared to 190 days for those continuing the drug.
A new study found that prostate cancer patients who underwent external beam radiation therapy were 70% more likely to develop rectal cancer and 40% more likely for bladder cancer. Survivors should be aware of symptoms such as pelvic pain, difficulty urinating, or blood in stool to monitor for potential secondary cancers.
The investigational agent DMOT4039A, a combination of chemotherapeutic agent and antibody, showed initial evidence of anti-cancer activity in a phase I clinical trial for pancreatic and ovarian cancers. The drug targets mesothelin-rich cancer cells, reducing the risk of off-target effects.
Researchers at the University of California, San Diego School of Medicine have identified two gene mutations that cause uveal melanoma, a type of eye cancer. They also found that an existing FDA-approved drug can slow tumor growth in experiments with mice.
Researchers at the University of Montreal have discovered a novel mechanism of drug resistance in leukemia and other cancers, which is driven by overactivity of the GLI1 gene. The team has identified drugs that can inhibit this gene's activity, potentially switching cancer cells back into sensitivity to existing chemotherapy.
Researchers have developed nanoscale structures called 'nanodaisies' that can deliver multiple anti-cancer drugs to cancer cells. These daisy-shaped structures show promise in treating lung, leukemia, breast, prostate, liver, ovarian and brain cancers.
Researchers have created an innovative 3D test system that allows them to simulate human body functions, enabling the development of more effective cancer treatments. The artificial lung model, no bigger than a sugar cube, can be used to analyze treatment resistance and metastasis formation, potentially leading to personalized medicine.
Cancer cells utilize a protein called Aiolos, which allows them to acquire blood cell characteristics and spread throughout the body. Researchers have discovered how this mechanism works, offering hope for future treatments.
Scientists have identified two genes, MLF2 and RPL39, that may affect the most lethal type of breast cancer. Suppressing these genes can reduce tumor formation and metastasis by interfering with blood vessel formation and recruitment.
Researchers at Yale Cancer Center presented findings from the 50th Annual Meeting of ASCO, highlighting the effectiveness of nivolumab and ipilimumab in treating advanced melanoma. Additionally, studies showed that lifestyle changes such as healthy eating and regular exercise can decrease biomarkers related to breast cancer recurrence ...
A phase I study found that alisertib inhibited aurora A kinase, a target for aggressive lymphoma treatment, in about one-third of patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia. The oral drug showed manageable side effects, paving the way for advanced trials.
A new centre, The Oxford Centre for Drug Delivery Devices (OxCD3), will be established to exploit engineering approaches to improve the therapeutic outcomes of drug-based cancer treatments. The centre aims to use stimulus-responsive nanocarriers and medical devices to enhance drug delivery into tumours.
Researchers at UC Berkeley have discovered the mechanism by which Taxol interferes with microtubule polymerization, preventing cell division in cancer cells. This finding could lead to the development of better anticancer drugs and improvements to existing treatments.
Researchers have successfully blocked autophagy in a range of aggressive cancers, including glioblastoma, melanoma, and myeloma, using hydroxychloroquine. The study shows that combining autophagy inhibitors with other cancer therapies can be safe and effective for patients with very sick cancers.
Researchers from VTT Technical Research Centre of Finland discover a new anticancer compound, Cent-1, that kills cancer cells through a similar mechanism to Rigosertib. This breakthrough uses computer-assisted screening and cell-based assays to accelerate drug discovery and potentially lower development costs.
Researchers used computer simulations to identify most effective drugs for brain cancer, considering genomic signatures and predicted sensitivities. The approach may help personalize therapies for cancer patients, selectively testing effective drugs while reducing exposure to toxic ones.
A team of researchers created a database called K-Map that allows scientists to reposition existing drugs to treat various types of cancer. The database enables the evaluation of rational drugs and drug combinations, leading to new potential treatments such as bosutinib for non-small cell lung cancer.
Researchers at Penn State have identified a pine bark substance, leelamine, that can simultaneously target multiple protein pathways in melanoma cells, shutting down their survival communication and leading to cell death. This unique approach may address the issue of resistance to current melanoma drugs.
Chemists at Scripps Research Institute have determined the correct structure of TIC10, a promising anticancer compound approved by FDA for clinical trials. The correct structure differs from an earlier published version and describes a molecule with potent anticancer effects in animals.
The Gordon Sondland and Katherine Durant Foundation has donated $1 million to the Oregon Health & Science University's Knight Cancer Institute to establish an annual research conference, drawing top thought leaders in cancer treatment. The conference aims to accelerate breakthroughs in early detection and treatment.
Cancer research calls on institutions to increase Hispanic patient enrollment, highlighting health disparities and underrepresentation in clinical trials. The study emphasizes the need for adequate representation to ensure effective treatment and reduce disparities.
Scientists used neutron scattering techniques to study mAb clustering, revealing extended clusters in high-viscosity solutions. The insights could help design devices for delivering biopharmaceuticals at high concentrations.
The University of Louisville has received a three-year, $5.5 million grant from the Leona M. and Harry B. Helmsley Charitable Trust to develop new treatments and vaccines for various forms of cancer. Researchers will focus on plant-based pharmaceuticals and vaccines for cervical and colon cancer.
Dr. Neal Meropol, Chief of Hematology and Oncology at Case Western Reserve University, is honored as an ASCO Fellow for his exceptional volunteer service and dedication to cancer care. He has served on the ASCO Board of Directors and various committees, contributing to the organization's mission to improve cancer care.
Researchers are testing whether therapy incorporating advanced genomic technology will provide better outcomes than current treatments for women with an aggressive form of breast cancer. The trial uses targeted DNA sequencing to identify specific treatment choices that improve survival rates.
Researchers developed a new technology that can generate visible light deep within the body, activating drugs and destroying tumors. This approach could greatly expand photodynamic therapy's effectiveness, offering fewer side effects and precise targeting of cancer cells.
Researchers found that PLX3397, a tyrosine kinase inhibitor, induced partial responses and stable disease in 79% of evaluable patients with advanced PVNS. The drug demonstrated significant tumor size reduction and minimal side effects.
A team of USC and NYU researchers has developed a small molecule that interferes with cancer progression by mimicking the surface topography of one protein, tricking another into binding with it. This stops an aberrant gene expression contributing to cancer growth with minimal side effects.
The University of Chicago Medicine Comprehensive Cancer Center has been awarded a five-year, $3.9-million grant to serve as a Lead Academic Participating Site for the National Clinical Trials Network. The new network aims to improve cancer clinical trials' speed and efficiency.
A new study reveals that US cervical cancer rates are higher than previously believed, particularly among women over 65 and African-American women. The study found an age-standardized rate of 18.6 cases of cervical cancer per 100,000 women, with incidence increasing steadily with age.
Researchers developed a novel anti-cancer drug delivery method using lipid-based nanocapsules to deliver drugs directly to cancer cells. The technique triggers the release of the drug, leading to cell death in breast cancer tumors. This efficient and fast-acting approach may improve treatment outcomes for cancer patients.
Researchers at Dartmouth's Norris Cotton Cancer Center have discovered a new epigenetic mechanism that distinguishes normal blood stem cells from blood cancers. This finding holds promise for developing targeted treatments that preserve healthy stem cells while killing leukemia cells.
Researchers develop nanoparticles that release two chemotherapy drugs, erlotinib and doxorubicin, at staggered times to weaken tumor cells' defenses before delivering DNA-damage. This approach dramatically shrinks lung and breast tumors in mice, including aggressive triple-negative breast cancer cells.
Using a novel bioinformatics approach, researchers have found that the approved antimicrobial drug pentamidine may help treat advanced kidney cancer. The study identified gene expression patterns that suggest an antimicrobial may be effective against clear cell renal cancer, a common and highly malignant subtype of kidney cancer.
Two UT Southwestern doctors have received grants to test the effectiveness of itraconazole on lung cancer pathways and growth. The researchers aim to disrupt communication between tumor cells and their surrounding environment, slowing cancer growth.
Researchers discovered microRNA-10a regulates human airway smooth muscle cell growth and inhibits PI3 kinase, a master regulator of cell proliferation. This finding offers a new approach to treating both asthma-induced muscle thickening and cancerous tumor growth.
Researchers have identified a key chemical that can repair damaged cell nuclei, a breakthrough in treating Hutchinson-Gilford Progeria Syndrome (HGPS), a rare and devastating ageing disease. The compound, Remodelin, also shows promise in reducing DNA damage and improving cellular health.
A new study reveals the link between obesity and increased risk of myeloma, a cancer of plasma cells. The researchers found that adiponectin, a protective protein, can be used to suppress fatty acid production in myeloma cells, leading to their demise.
Researchers at Georgetown University Medical Center have identified Yes-associated protein (Yes) as the critical switch that promotes cancer growth and progression in pancreatic ductal adenocarcinoma (PDAC). Inhibiting Yes completely shuts down further growth of pancreatic cancer, offering a promising therapeutic target.
Advances in biological imaging enable scientists to identify the most promising new drugs and rule out those unlikely to work, potentially improving the success rate of cancer medicines. Researchers are using this approach to streamline the drug discovery process, reducing costs and side effects.
A study of 67 transplant patients found those with naturally high levels of HLA-G dimer, a powerful immune molecule package, had the lowest risk of rejecting their transplanted kidney. High HLA-G levels also correlated with lower inflammation and higher expression of HLA-G receptors.
Biologists have identified a crucial outer shield on T-type channels that influences the electrochemical signaling of heart and brain cells. This finding holds promise for developing new drugs to treat epilepsy, cardiovascular disease, and cancer by targeting this regulator.
Researchers at Drexel University have created a method for 3D printing living cancer tumors using cervical cancer cells and hydrogel substances. This breakthrough technology allows for more accurate modeling of tumor behavior and response to treatment, potentially leading to new paradigms for cancer research and individual therapies.
Researchers have uncovered how cells block mutation-causing activity of junk DNA, a process involving an enzyme called APOBEC3A. This defense mechanism may help explain a long-standing mystery and has potential implications for cancer treatment.
Moffitt Cancer Center's phase 3 study shows CPX-351 leads to higher remission rates compared to standard options in AML, offering a new game-changer for treatment. The innovative drug combination works by maintaining an optimal ratio of cytarabine and daunorubicin inside lipid vesicles.
Researchers at National University of Singapore identify cancer-specific stem cell causing gastric cancer, opening possibility of developing new drugs to treat this disease. They discovered a cancer-specific variant of a cell surface protein, CD44v8-10, marks gastric cancer stem cells but not normal cells.
Researchers at Harvard's Wyss Institute have successfully created DNA nanodevices that can survive the body's immune defenses long enough to perform diagnostic or therapeutic tasks. The devices use a virus-like cloaking strategy to evade the immune system and deliver drugs directly to diseased tissues.
Researchers found that false-positive mammograms have a temporary and limited impact on women's overall health and well-being. The study also showed that women who experience a false positive may actually be more likely to use breast cancer screening in the future.
Researchers at the University of Pittsburgh discovered a malfunction in the molecular 'proofreading' machinery that repairs DNA damage caused by ultraviolet (UV) light. The protein UV-DDB makes stops along the DNA strand and transiently attaches to it, causing a proofreading change in its conformation, preventing repair in damaged areas.
Researchers have discovered a new role for Cullin-5 in killing cancer cells by targeting proteins that drive cell division. The study suggests a possible test to identify responsive patients and develop more effective drugs.
Scientists have identified a molecule called CD61 on the surface of drug-resistant tumors that induces tumor metastasis by enhancing cancer cell properties. The findings suggest that existing drugs can exploit this pathway to reverse drug resistance and re-sensitize tumors.